[1]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估[J].医学信息,2018,31(15):132-134.[doi:10.3969/j.issn.1006-1959.2018.15.042]
　ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(15):132-134.[doi:10.3969/j.issn.1006-1959.2018.15.042]
点击复制

多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的 疗效和安全性评估()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年15期
页码:
132-134
栏目:
药物与临床
出版日期:
2018-08-01

文章信息/Info

Title:
Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer
文章编号:
1006-1959（2018）15-0132-03
作者:
朱淑娟
佳木斯肿瘤医院肿瘤内科，黑龙江 佳木斯 154007
Author(s):
ZHU Shu-juan
Department of Oncology,Jiamusi Cancer Hospital,Jiamusi 154007,Heilongjiang,China
关键词:
晚期非小细胞肺癌; 恶性胸腔积液; 多西他赛; 安全性
Keywords:
Key words：Advanced non-small cell lung cancer; Malignant pleural effusion; Docetaxel; Safety
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2018.15.042
文献标志码:
A
摘要:
目的 研究多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的疗效和安全性。方法 将2016年1月~12月本院接收的晚期非小细胞肺癌恶性胸腔积液患者152例，根据按照电脑随机分组原则分为两组，每组76例。两组均行胸腔穿刺术，对照组给予培美曲塞，观察组给予多西他赛治疗。将两组患者的临床疗效、不良反应发生情况和ECOG评分进行比对。结果 观察组晚期非小细胞肺癌恶性胸腔积液患者的临床总有效率89.47%，高于对照组的65.79%，差异有统计学意义（P＜0.05）；胃肠道反应、胸痛、肾毒性不良反应的发生率和治疗后ECOG评分均低于对照组，差异有统计学意义（P＜0.05）。结论 多西他赛应用在晚期非小细胞肺癌恶性胸腔积液患者中取得疗效确切，临床安全性较高。
Abstract:
Abstract：Objective To study the efficacy and safety of docetaxel in the control of malignant pleural effusion in patients with advanced non-small cell lung cancer.Methods 152 patients with malignant pleural effusion of advanced non-small cell lung cancer received in our hospital from January to December 2016 were divided into two groups according to the principle of computer random grouping,76 cases in each group.Thoracic puncture was performed in both groups,pemetrexide was given in control group and docetaxel was given in observation group.The clinical efficacy,adverse reaction and ECOG score were compared between the two groups.Results The total effective rate of the patients with malignant pleural effusion of non-small cell lung cancer in the observation group was 89.47%,which was higher than that of the control group 65.79%,the difference was statistically significant(P<0.05).The incidence of gastrointestinal reactions,chest pain and nephrotoxic adverse reactions and the ECOG score after treatment were lower than those of the control group,the difference was statistically significant(P<0.05).Conclusion Docetaxel is effective and safe in the treatment of advanced non-small cell lung cancer with malignant pleural effusion.

参考文献/References:

[1]张俊.奈达铂联合多西他赛治疗老年晚期非小细胞肺癌的疗效观察[J].中国实用医药,2017,12(30):101-102.
[2]岳瑞清.晚期非小细胞肺癌应用多西他赛单药和多西他赛联合顺铂二线治疗的效果研究[J].山西医药杂志,2016,45(16):1911-1913.
[3]王霖.培美曲塞二钠和多西他赛单药维持治疗晚期非小细胞肺癌的临床观察[C]//航天护理年会.2017.
[4]麦泽锋.消癌平注射液联合多西他赛治疗晚期非小细胞肺癌的临床观察[J].国际肿瘤学杂志,2017,44(7):557-558.
[5]周强,孙浩珍.多西他赛注射剂治疗晚期非小细胞肺癌的临床研究[J].中国临床药理学杂志,2016,32(21):1964-1966.
[6]徐旭.多西他赛胸腔灌注联合热疗治疗恶性胸腔积液的临床疗效观察[J].医药前沿,2017,7(2):180-181.
[7]颜劲,麦卫校,郁小凤.吉非替尼与多西他赛二线治疗晚期非小细胞肺腺癌的临床效果分析[J].北方药学,2016,13(11):93-94.
[8]张纪良,青小燕,曾晓梅,等.洛铂联合多西他赛治疗晚期非小细胞肺癌疗效的观察[J].中国医药导刊,2017,19(2):165-167.

相似文献/References:

[1]李雪芹,王存德,龚 泉,等.鸦胆子油乳注射液配合恩度治疗恶性胸腔积液的临床分析[J].医学信息,2018,31(03):13.[doi:10.3969/j.issn.1006-1959.2018.03.005]
　LI Xue-qin,WANG Cun-de,GONG Quan,et al.Clinical Analysis of Brucea Javanica Oil Emulsion Injection Combined with Endor in the Treatment of Malignant Pleural Effusion[J].Journal of Medical Information,2018,31(15):13.[doi:10.3969/j.issn.1006-1959.2018.03.005]
[2]党升强,崔立春,魏 琳,等.同步放化疗联合扶正肺癌方治疗局部晚期非小细胞肺癌的效果[J].医学信息,2019,32(24):166.[doi:10.3969/j.issn.1006-1959.2019.24.061]
　DANG Sheng-qiang,CUI Li-chun,WEI Lin,et al.Effect of Concurrent Chemoradiotherapy and Fuzheng Lung Cancer Recipe on Locally Advanced Non-Small Cell Lung Cancer[J].Journal of Medical Information,2019,32(15):166.[doi:10.3969/j.issn.1006-1959.2019.24.061]
[3]罗 超,葛明建.非小细胞肺癌干性胸膜转移的研究现状[J].医学信息,2021,34(03):31.[doi:10.3969/j.issn.1006-1959.2021.03.010]
　LUO Chao,GE Ming-jian.Research Status of Stem Pleural Metastasis of Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(15):31.[doi:10.3969/j.issn.1006-1959.2021.03.010]
[4]刘志坚,刘海燕,宿抱玉.阿帕替尼联合多西他赛治疗晚期非小细胞肺癌疗效和安全性的Meta分析[J].医学信息,2021,34(07):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
　LIU Zhi-jian,LIU Hai-yan,SU Bao-yu.Meta-analysis of the Efficacy and Safety of Apatinib Combined with Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(15):10.[doi:10.3969/j.issn.1006-1959.2021.07.003]
[5]石少庆.甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果[J].医学信息,2023,36(01):152.[doi:10.3969/j.issn.1006-1959.2023.01.032]
　SHI Shao-qing.Clinical Effect of Apatinib Mesylate Tablets in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(15):152.[doi:10.3969/j.issn.1006-1959.2023.01.032]
[6]苏 凝,樊利萍,秦丽丽,等.恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效[J].医学信息,2021,34(11):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
　SU Ning,FAN Li-ping,QIN Li-li,et al.Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Journal of Medical Information,2021,34(15):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
[7]王会敏,徐 克,穆 红.恩度联合顺铂局部治疗对非小细胞肺癌合并恶性胸腔积液肿瘤标志物的影响[J].医学信息,2021,34(16):106.[doi:10.3969/j.issn.1006-1959.2021.16.028]
　WANG Hui-min,XU Ke,MU Hong.Effect of Endo and Cisplatin Local Therapy on Tumor Markers of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Journal of Medical Information,2021,34(15):106.[doi:10.3969/j.issn.1006-1959.2021.16.028]
[8]史建强,胡 云.扶正解毒汤辅助克唑替尼对晚期非小细胞肺癌患者临床疗效及对血清肿瘤标志物的影响[J].医学信息,2023,36(16):137.[doi:10.3969/j.issn.1006-1959.2023.16.027]
　SHI Jian-qiang,HU Yun.Clinical Efficacy of Fuzheng Jiedu Decoction Combined with Crizotinib in the Treatment of Patients with Advanced Non-small Cell Lung Cancer and its Effect on Serum Tumor Markers[J].Journal of Medical Information,2023,36(15):137.[doi:10.3969/j.issn.1006-1959.2023.16.027]
[9]徐怡英.程序性死亡蛋白-1抑制剂治疗晚期非小细胞肺癌的临床疗效及安全性[J].医学信息,2023,36(23):115.[doi:10.3969/j.issn.1006-1959.2023.23.029]
　XU Yi-ying.Clinical Efficacy and Safety of Programmed Death Protein-1 Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(15):115.[doi:10.3969/j.issn.1006-1959.2023.23.029]
[10]雷希君,罗利琼.腔内灌注治疗恶性胸腔积液的研究现状[J].医学信息,2024,37(03):184.[doi:10.3969/j.issn.1006-1959.2024.03.039]
　LEI Xi-jun,LUO Li-qiong.Research Status of Intracavitary Perfusion in the Treatment of Malignant Pleural Effusion[J].Journal of Medical Information,2024,37(15):184.[doi:10.3969/j.issn.1006-1959.2024.03.039]

更新日期/Last Update: 2018-08-01